home / stock / irwd / irwd news


IRWD News and Press, Ironwood Pharmaceuticals Inc. From 08/05/22

Stock Information

Company Name: Ironwood Pharmaceuticals Inc.
Stock Symbol: IRWD
Market: NASDAQ
Website: ironwoodpharma.com

Menu

IRWD IRWD Quote IRWD Short IRWD News IRWD Articles IRWD Message Board
Get IRWD Alerts

News, Short Squeeze, Breakout and More Instantly...

IRWD - Ironwood Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation

IRWD - Ironwood Pharmaceuticals reports Q2 earnings miss; reaffirms FY22 guidance

Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q2 Non-GAAP EPS of $0.21 misses by $0.09 . Revenue of $97.23M (-6.5% Y/Y) misses by $6.28M . Adjusted EBITDA was $56.0 million in the second quarter of 2022, compared to $65.2 million in the second quarte...

IRWD - Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand

– LINZESS (Iinaclotide) EUTRx prescription demand growth in Q2 2022 increased 9% year-over-year – – GAAP net income of $37 million and adjusted EBITDA of $56 million; ended Q2 2022 with $504 million in cash and cash equivalents – –...

IRWD - Ironwood Pharmaceuticals Q2 2022 Earnings Preview

Ironwood Pharmaceuticals ( NASDAQ: IRWD ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.30 (-11.8% Y/Y) and the consensus Revenue Estimate is $103.51M (-0.5% Y/Y). Over the last 2 years, IRWD ...

IRWD - Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

Ironwood Pharmaceuticals ( NASDAQ: IRWD ) is trading down 7% after AbbVie ( ABBV ) Friday morning reported Q2 2022 revenue of Linzess (linaclotide) -- which is marketed by both companies -- that came in below analyst consensus estimates. Linzess and Constella (...

IRWD - Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 4, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. ...

IRWD - LI, VICI and PDD among pre market gainers

DiDi Global DIDI +61% as Beijing looks to end cybersecurity probe. Yumanity Therapeutics YMTX+42% on all-stock merger with Kineta; lead product sale to J&J for $26M. Full Truck Alliance YMM +26% as Beijing looks to end cybersecurity probe. Kanzhun Limited BZ ...

IRWD - Keurig Dr Pepper, VICI Properties and ON Semiconductor Set to Join S&P 500; Others to Join S&P MidCap 400, and S&P SmallCap 600

Keurig Dr Pepper, VICI Properties and ON Semiconductor Set to Join S&P 500; Others to Join S&P MidCap 400, and S&P SmallCap 600 Keurig Dr Pepper, VICI Properties and ON Semiconductor Set to Join S&P 500; Others to Join S&P MidCap 400, and S&P SmallCap 600...

IRWD - ON Semi, VICI, Keurig Dr Pepper jump on S&P 500 additions

Big changes are afoot in the S&P 500, as Dow Jones Indices shuffles three companies in and out of the index. ON Semiconductor (NASDAQ:ON) is up 6.5% after hours; VICI Properties (NYSE:VICI) is up 6.2%; and Keurig Dr Pepper (NASDAQ:KDP) is up 5.4% postmarket as all three companies make the...

IRWD - Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022

– Other Studies Highlight Impact of Linaclotide in Adult and Pediatric Populations, Highlight Disease Burden – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented new findings during the 2022 Digestive Disease Week &#...

Previous 10 Next 10